Αρχική World News Spending Review 2021: Promising commitments, but a lot of unanswered questions

Spending Review 2021: Promising commitments, but a lot of unanswered questions

Today, the Government set out its spending plans for the next 3 years.

We saw the Comprehensive Spending Review (CSR) as an opportunity to put the UK on a path towards better cancer survival, through growing the cancer workforce and investing in diagnostic equipment, research and public health.

It was billed as the moment the Government would set out how it was going to ‘build back better’ – critical, given this is likely to be the last spending review before the next General Election.

So, did the Government deliver?

The picture is still emerging and we don’t have a full sense yet of what each announcement will mean, but broadly it looks promising. Here’s what we know right now.

Progress on diagnostic equipment

On diagnostic kit, we estimated that Government needed to invest at least £1.3 billion just to reach the average number of scanners compared to other countries. And a figure likely in the billions to fully roll out innovative ‘one stop shop’ Community Diagnostic Centres.

In positive news, earlier this week the Chancellor announced £2.3 billion across the next 3 years for transforming diagnostic services, investment meant to set up at least 100 new Community Diagnostic Centres across England.

‘One stop shop’ diagnostic centres have the potential not only to expand capacity, with welcome new scanners, blood testing labs, endoscopy suites and other important testing kit. They will also bring diagnostic tests together in new sites set in communities across the country – helping patients more easily access these key cancer tests.

This money was accompanied by another £1.5 billion to expand the number of beds in NHS hospitals and set up new surgical hubs with extra theatres to tackle backlogs in urgent procedures, which could make important progress in tackling growing waits for cancer patients.

Early positive signs on workforce, but clarity needed

Of course, the new equipment will need an expanded cancer workforce to operate it – and here there’s also some positive signs, but with a lot of uncertainty remaining.

We estimated that the Government needed to invest around £216 million across the next 3 years into training a cancer workforce able to deliver world class cancer care.

Today, the Government announced there will be ‘hundreds of millions of pounds of additional funding’ to build a bigger, better trained NHS workforce.

A promising commitment, but it’s still far from clear how this money will be targeted – meaning we don’t yet know whether this increased investment will see growing numbers of staff in the cancer workforce. We will be pushing for that to be the case.

Now the Government and the NHS need to urgently clarify that today’s announcement will deliver the vital investment needed to grow the cancer workforce. This will be key to turning their commitments to improve cancer outcomes into reality.

Boosting research and innovation – but not as much as promised

In his speech, the Chancellor committed to spend £20 billion in R&D by 2025, and £22bn by 2027. While this is a disappointing scale back of what was originally promised (£22 billion by 2025), it is still a strong boost to R&D funding with a clear trajectory for spending increases.

Within this, £5 billion for health research over the next 3 years has been allocated, which represents a £1.2 billion increase between now and 2025. This funding includes £95 million to deliver the Government’s ‘Life Sciences Vision’, including its commitments to cancer, as well as £30 million for the National Institute for Health Research to invest in research skills and training for healthcare staff underrepresented in research.

While a lot depends on how and when this spending is distributed, this increase in health research could provide much-needed support for cancer researchers and help strengthen the UK’s ability to improve cancer outcomes through research.

Investment in public health

Preventable disease continues to have a massive impact on our nation’s health, the NHS and the wider economy – something that only became clearer during the pandemic.

Despite this, the Spending Review announced no real terms increase in the public health grant. This follows the significant cuts Local Government has experienced in recent years, with the most deprived local authorities facing the most severe reductions.

Vital services – like those that can help people stop smoking, maintain a healthy weight and manage their alcohol intake – are experiencing severe strain and this will do nothing to relieve it. The Chancellor has also missed a key opportunity to undo the damage to public health and to Government revenues of years of alcohol duty freezes.

And while we were pleased to see an increase in tobacco taxes, it’s nowhere near what will be required to make smoking obsolete. That’s because increasing taxes is just one piece of puzzle – what we need are tobacco control comprehensive strategies with services to help people quit smoking, something this money won’t be specifically earmarked for.

We’ve been calling for a dedicated fund – making the highly profitable tobacco companies pay for the damage they cause – for years. This would use industry funds, but without industry interference. However, disappointingly there’s been no dedicated investment in tobacco control.

Unless remedied for the upcoming Tobacco Control Plan for England – this will seriously threaten the UK’s ability to achieve smokefree ambitions and reduce smoking-related health disparities.

What next?

While there are still some unanswered questions following today’s Spending Review, on the whole, Government has made a number of positive commitments on cancer services and research.

Now, we’ll be working with Government and the NHS to fully understand exactly what the commitments made today will mean for cancer patients and research now and in the years to come. And we’ll be working hard to ensure that any investment delivers for cancer patients, in both building better cancer services and supporting life-saving cancer research.

A critical test will be whether these announcements will help met the Government ambition to diagnose 3 in 4 cancers early by 2028 and whether they help meet their manifesto commitment to improve cancer survival in this country.

The announcements today are also specifically for England, meaning there’s more work for us to ensure that the vital investment seen today in growing the cancer workforce and securing more vital diagnostic kit is replicated in budgets in Wales, Scotland and Northern Ireland.

Thank you

Where there have been wins today, they belong to the whole cancer community. Cancer charities large and small have united behind the One Cancer Voice and All-Party Parliamentary Group coalitions.

Campaigners outside Westminster.

One Cancer Voice campaigners handing in our petition to Parliament.

Our Campaign Ambassadors have led our #CancerWontWait campaign, sharing their personal stories and meeting their MPs to help ensure cancer remains at the top of the political and policy agenda. And tens of thousands of people added their voices to our petition.

Together, we’ve been relentless in our campaigning to secure investment in cancer services.

What today has shown is that when we speak with one voice, we can start to make real progress.

More on this topic



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

2-Year-Boy Is So Excited To See Himself In Disney’s ‘Encanto’

The importance of representation in media has been a growing topic of concern, and companies have responded by adding more diversity to their characters,...

Man Walks Entire Continent To Spread Awareness About Mental Health & Suicide Prevention

Matthew Fennell is walking over 3,000 miles across Australia for an important cause and one that is near and dear to his heart. Last year,...

Boy Battling Cancer Becomes Honorary Police Officer, Sworn In To 45 Agencies

At just ten years old, Devarjaye “DJ” Daniel has already been through more than most people go through in their entire lives. DJ has been...

Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide for the Treatment of Patients with Uterine Carcinosarcoma

With regard to overall survival (OS), paclitaxel and carboplatin was not inferior and demonstrated improved progression-free survival (PFS) when compared with paclitaxel and ifosfamide...

Cancer in My Community: Improving Access to Palliative Care in Indonesia

Cancer in My Community is a Cancer.Net Blog series that shows the global impact of cancer and how people work to care for those with...

Should CAR T Cells Be Used Earlier in People with Non-Hodgkin Lymphoma?

January 13, 2022, by NCI Staff Several approved CAR T-cell therapies work by binding to the CD19 antigen on cancer cells and killing them. Credit: Adapted...